IV 튜브 세트 및 부속품 시장 : 제품 유형, 재질, 용도, 최종 사용자, 유통 채널별 - 세계 시장 예측(2026-2032년)

The IV Tubing Sets & Accessories Market is projected to grow by USD 2.43 billion at a CAGR of 5.86% by 2032.

Executive Introduction to IV Tubing Sets & Accessories

IV tubing sets and accessories form a mission-critical layer of infusion therapy, connecting medications, fluids, blood products, parenteral nutrition, and contrast media to patients across hospitals, ambulatory surgery centers, oncology clinics, dialysis settings, emergency care, and home infusion programs. Demand is anchored in verifiable healthcare realities, including rising chronic disease treatment intensity, expanding surgical volumes, aging populations, and the continued shift of complex care from inpatient wards to outpatient and home-based models.

Market attention is moving beyond basic IV administration sets toward precision, safety, and compatibility. Healthcare providers are prioritizing IV extension sets, needleless connectors, stopcocks, filters, pressure-rated tubing, anti-siphon and anti-free-flow features, and closed-system transfer components that align with medication safety, infection prevention, and occupational exposure standards. For manufacturers and distributors, competitive differentiation increasingly depends on regulatory compliance, supply continuity, human-factor design, pump interoperability, and material transparency across the entire IV therapy workflow.

Transformative Shifts in the IV Therapy Landscape

The IV tubing sets and accessories landscape is being reshaped by four validated forces: infection prevention, medication safety, regulatory modernization, and site-of-care migration. Guidance from public health, medication safety, and accreditation bodies continues to reinforce aseptic technique, line integrity, labeling, and safe handling of hazardous drugs. These requirements are driving adoption of needleless access systems, closed connectors, low-dead-space designs, and products that reduce manipulation of vascular access points.

At the same time, procurement teams are reassessing resilience after documented medical supply disruptions during global health emergencies. Hospitals and purchasing organizations are favoring suppliers with diversified manufacturing, transparent sterilization capacity, UDI-enabled traceability, and validated quality systems. The shift toward smart infusion pumps and electronic medication administration records is also creating demand for tubing sets that support standardized workflows, barcode scanning, pressure management, and reduced risk of misconnections under ISO-aligned connector standards.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the IV tubing sets and accessories value chain cumulatively rather than as a single disruptive event. In manufacturing, AI-supported vision inspection, statistical process control, and predictive maintenance help detect molding defects, particulate risks, seal variability, and packaging anomalies earlier in production. These applications support quality assurance objectives required under recognized medical device quality systems and comparable regulatory frameworks.

In commercial operations, AI improves demand planning for high-turnover infusion consumables by combining procedure trends, hospital census signals, seasonal illness patterns, and distributor inventory data. In clinical environments, AI embedded in infusion platforms can support dose-error reduction, occlusion-risk alerts, and pump utilization analytics, indirectly raising expectations for tubing compatibility and performance consistency. The long-term impact is a more data-driven ecosystem in which IV set design, inventory planning, adverse-event surveillance, and post-market monitoring become increasingly connected.

Key Regional Insights Across Global Markets

North America remains one of the most mature regions for IV tubing sets and accessories, supported by high hospital procedure volumes, widespread infusion pump adoption, strong home infusion infrastructure, and rigorous medical device oversight. The United States drives demand through oncology care, biologics administration, emergency medicine, and outpatient infusion centers, while Canada emphasizes publicly funded procurement, safety standardization, and supply reliability.

Europe is shaped by the EU Medical Device Regulation, national health technology assessment practices, and sustainability expectations that are influencing materials, packaging, and supplier documentation. Asia-Pacific is a fast-evolving opportunity zone, with China, India, Japan, South Korea, Australia, and ASEAN markets expanding access to hospital care, specialty infusion therapy, and domestic medical device production. Latin America, led by Brazil and Mexico, shows momentum tied to private hospital investment and public health modernization, while the Middle East is supported by GCC hospital expansion, specialty care investment, and medical tourism. Africa presents longer-term potential as health systems invest in essential hospital infrastructure, infection control, and reliable distribution networks.

Key Group Insights for Strategic Market Positioning

ASEAN markets are benefiting from healthcare infrastructure investment, regional medical device regulatory harmonization efforts, and growing private hospital networks in countries such as Indonesia, Thailand, Vietnam, Malaysia, and the Philippines. These conditions favor scalable IV administration sets, extension lines, and safety accessories that balance affordability with compliance and distributor reach.

The GCC is characterized by high investment in tertiary hospitals, oncology centers, and digitally enabled care, creating demand for premium infusion accessories and standardized procurement. The European Union is defined by MDR compliance, CE-marking scrutiny, and sustainability-oriented purchasing. BRICS economies combine large patient populations with expanding domestic manufacturing ambitions, making localization, cost efficiency, and regulatory navigation central to supplier success. G7 markets typically set the benchmark for quality, traceability, and clinical safety expectations, while NATO members add relevance in emergency preparedness, field medicine, and resilient medical supply chains.

Key Country Insights for IV Tubing Sets & Accessories

The United States is a leading country market for advanced IV tubing sets and accessories due to high procedure intensity, established home infusion reimbursement pathways, and strong adoption of smart infusion systems. Canada prioritizes standardized purchasing and patient safety, while Mexico benefits from nearshoring, private hospital growth, and cross-border supply chain integration. Brazil is Latin America's largest healthcare market and shows demand for both cost-effective and premium infusion products across public and private providers.

In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain mature hospital networks with increasing focus on MDR-compliant devices, sustainability, and medication safety. Russia presents demand through large hospital infrastructure needs but faces procurement and trade complexities. China is scaling domestic medical device capabilities and high-volume hospital purchasing, India is expanding access through public insurance and private hospital networks, Japan emphasizes quality and aging-related care demand, Australia relies on safety-driven procurement, and South Korea combines advanced hospital technology with strong domestic medical device capabilities.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize product portfolios that address infection prevention, medication safety, and workflow efficiency in a single value proposition. High-impact opportunities include needleless connectors, closed-system compatible accessories, DEHP-free and latex-free tubing, pressure-rated sets, low-sorption materials for specialty drugs, and standardized connectors that reduce misconnection risk.

Manufacturers should strengthen supplier redundancy, sterilization capacity planning, and UDI-based traceability to meet hospital expectations for resilience. Commercial teams should segment buyers by care setting, because inpatient critical care, outpatient oncology, ambulatory surgery, emergency medicine, and home infusion each require different tubing performance features. Leaders should also invest in evidence generation, human-factors validation, pump compatibility testing, and AI-enabled demand planning to improve both clinical credibility and inventory availability.

Research Methodology

This executive summary is developed using a structured secondary-research methodology aligned with medical device market intelligence practices. Inputs include publicly available regulatory guidance, medical device quality standards, healthcare infrastructure indicators, infection prevention recommendations, procurement patterns, clinical workflow requirements, and documented trends in infusion therapy, home healthcare, oncology, and surgical care.

The analysis triangulates demand-side indicators such as hospital utilization, chronic disease treatment pathways, ambulatory care expansion, and medication safety requirements with supply-side indicators such as manufacturing capability, regulatory compliance, sterilization, distribution resilience, and post-market surveillance. Regional, group, and country insights are synthesized from verifiable policy and market structure factors rather than unsupported projections.

Conclusion

The IV tubing sets and accessories market is evolving from a commodity consumables category into a safety-critical, data-informed, and regulation-sensitive segment of infusion therapy. Demand is supported by the increasing volume and complexity of IV treatments, while differentiation is defined by infection prevention, pump compatibility, material performance, and dependable supply.

Organizations that combine compliant manufacturing, clinically relevant innovation, and resilient distribution will be best positioned to serve hospitals, ambulatory networks, and home infusion providers. As AI, digital procurement, and connected infusion systems mature, the market will increasingly reward suppliers that can prove quality, availability, and measurable workflow value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. IV Tubing Sets & Accessories Market, by Product Type

• 7.1. Primary IV Tubing Sets
• 7.2. Secondary IV Tubing Sets
• 7.3. Extension IV Tubing Sets
• 7.4. IV Tubing Accessories
  • 7.4.1. Needleless Connectors
  • 7.4.2. Stopcocks
  • 7.4.3. IV Filters
  • 7.4.4. Clamps

8. IV Tubing Sets & Accessories Market, by Material Type

• 8.1. Polyethylene
• 8.2. Polyurethane
• 8.3. PVC
• 8.4. Silicone

9. IV Tubing Sets & Accessories Market, by Application

• 9.1. Peripheral Intravenous Therapy
  • 9.1.1. Hydration Therapy
  • 9.1.2. Antibiotic Delivery
  • 9.1.3. Pain Management
• 9.2. Central Venous Access
  • 9.2.1. ICU Infusions
  • 9.2.2. Hemodynamic Monitoring
• 9.3. PICC Line Infusion
• 9.4. Parenteral Nutrition
• 9.5. Chemotherapy

10. IV Tubing Sets & Accessories Market, by End User

• 10.1. Ambulatory Surgical Centers
• 10.2. Clinics
• 10.3. Home Healthcare
• 10.4. Hospitals
  • 10.4.1. Private
  • 10.4.2. Public

11. IV Tubing Sets & Accessories Market, by Channel Of Distribution

• 11.1. Online
  • 11.1.1. Manufacturer Website
  • 11.1.2. eCommerce Platforms
• 11.2. Offline

12. IV Tubing Sets & Accessories Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. IV Tubing Sets & Accessories Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. IV Tubing Sets & Accessories Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AdvaCare Pharma
• 16.2. Amsino International, Inc.
• 16.3. AngioDynamics, Inc.
• 16.4. B. Braun Melsungen AG
• 16.5. Baxter International Inc.
• 16.6. Becton, Dickinson and Company
• 16.7. BQ PLUS MEDICAL CO., LTD.
• 16.8. Cardinal Health, Inc.
• 16.9. Codan Medizinische Gerate GmbH
• 16.10. Fresenius Kabi AG
• 16.11. ICU Medical, Inc.
• 16.12. Medline Industries, LP
• 16.13. Moog Inc.
• 16.14. Nipro Corporation
• 16.15. Smiths Group plc
• 16.16. Terumo Corporation
• 16.17. Vygon SA